Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Abstract Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the latest and a vital treatment option for non-small cell lung cancer (NSCLC) patients. Although EGFR-sensitive mutations are an indication for third-generation EGFR-TKI therapy, 30% of NSCLC patie...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-12-01
|
| Series: | Scientific Data |
| Online Access: | https://doi.org/10.1038/s41597-024-04169-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850244528725819392 |
|---|---|
| author | Ning Lou Ruyun Gao Yuankai Shi Xiaohong Han |
| author_facet | Ning Lou Ruyun Gao Yuankai Shi Xiaohong Han |
| author_sort | Ning Lou |
| collection | DOAJ |
| description | Abstract Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the latest and a vital treatment option for non-small cell lung cancer (NSCLC) patients. Although EGFR-sensitive mutations are an indication for third-generation EGFR-TKI therapy, 30% of NSCLC patients lack response and all patients inevitably progress. There is a lack of biomarkers to predict the efficacy of EGFR-TKI therapy. In this report, we performed comprehensive plasma metabolomic profiling on 186 baseline and 20 post-treatment samples, analyzing 1,019 metabolites using four ultrahigh performance liquid chromatography-tandem mass spectroscopy (UPLC-MS/MS) methods. The dataset contains detailed clinical and metabolic information for 186 patients. Rigorous quality control measures were implemented. No significant differences in body mass index and biochemical metabolic parameters were observed between responders and non-responders. The datasets were utilized to characterize the responsive metabolic traits of third-generation EGFR-TKI therapy. All datasets are available for download on the OMIX website. We anticipate that these datasets will serve as valuable resources for future studies investigating NSCLC metabolism and for the development of personalized therapeutic strategies. |
| format | Article |
| id | doaj-art-a7444eef336e47c49daa474401304eda |
| institution | OA Journals |
| issn | 2052-4463 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Data |
| spelling | doaj-art-a7444eef336e47c49daa474401304eda2025-08-20T01:59:43ZengNature PortfolioScientific Data2052-44632024-12-011111710.1038/s41597-024-04169-0Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKINing Lou0Ruyun Gao1Yuankai Shi2Xiaohong Han3Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College; No.1, Shuaifuyuan, Dongcheng DistrictDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; No. 17 Panjiayuan Nanli, Chaoyang DistrictDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; No. 17 Panjiayuan Nanli, Chaoyang DistrictClinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College; No.1, Shuaifuyuan, Dongcheng DistrictAbstract Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the latest and a vital treatment option for non-small cell lung cancer (NSCLC) patients. Although EGFR-sensitive mutations are an indication for third-generation EGFR-TKI therapy, 30% of NSCLC patients lack response and all patients inevitably progress. There is a lack of biomarkers to predict the efficacy of EGFR-TKI therapy. In this report, we performed comprehensive plasma metabolomic profiling on 186 baseline and 20 post-treatment samples, analyzing 1,019 metabolites using four ultrahigh performance liquid chromatography-tandem mass spectroscopy (UPLC-MS/MS) methods. The dataset contains detailed clinical and metabolic information for 186 patients. Rigorous quality control measures were implemented. No significant differences in body mass index and biochemical metabolic parameters were observed between responders and non-responders. The datasets were utilized to characterize the responsive metabolic traits of third-generation EGFR-TKI therapy. All datasets are available for download on the OMIX website. We anticipate that these datasets will serve as valuable resources for future studies investigating NSCLC metabolism and for the development of personalized therapeutic strategies.https://doi.org/10.1038/s41597-024-04169-0 |
| spellingShingle | Ning Lou Ruyun Gao Yuankai Shi Xiaohong Han Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI Scientific Data |
| title | Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI |
| title_full | Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI |
| title_fullStr | Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI |
| title_full_unstemmed | Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI |
| title_short | Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI |
| title_sort | plasma metabolomics profiling of egfr mutant nsclc patients treated with third generation egfr tki |
| url | https://doi.org/10.1038/s41597-024-04169-0 |
| work_keys_str_mv | AT ninglou plasmametabolomicsprofilingofegfrmutantnsclcpatientstreatedwiththirdgenerationegfrtki AT ruyungao plasmametabolomicsprofilingofegfrmutantnsclcpatientstreatedwiththirdgenerationegfrtki AT yuankaishi plasmametabolomicsprofilingofegfrmutantnsclcpatientstreatedwiththirdgenerationegfrtki AT xiaohonghan plasmametabolomicsprofilingofegfrmutantnsclcpatientstreatedwiththirdgenerationegfrtki |